Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q93009
UPID:
UBP7_HUMAN
Alternative names:
Deubiquitinating enzyme 7; Herpesvirus-associated ubiquitin-specific protease; Ubiquitin thioesterase 7; Ubiquitin-specific-processing protease 7
Alternative UPACC:
Q93009; A6NMY8; B7Z815; H0Y3G8
Background:
Ubiquitin carboxyl-terminal hydrolase 7 (UCHL7), also known as Deubiquitinating enzyme 7, plays a pivotal role in cellular processes by deubiquitinating and stabilizing various proteins including p53/TP53, FOXO4, and PTEN. Its activity is crucial for transcription regulation, cell growth repression, apoptosis, and DNA repair mechanisms.
Therapeutic significance:
UCHL7's involvement in Hao-Fountain syndrome, a neurodevelopmental disorder with seizures and intellectual disability, underscores its therapeutic potential. Understanding UCHL7's role could open doors to novel therapeutic strategies for treating this syndrome and possibly other related neurological conditions.